VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered into a distribution agreement with PolyMedics Innovations GmbH, to strategically expand its global presence to Europe.
Under the terms of the agreement, PolyMedics Innovations will serve as the Company’s exclusive distributor of RECELL® in Germany, Austria, and Switzerland, with an option to expand to additional European markets in the future.
PolyMedics Innovations, a privately-owned company specializing in the commercialization of innovative biomaterials and systems for the treatment of wounds, operates a robust distribution network of over 40 global markets. AVITA Medical will leverage their deep expertise, well-established infrastructure, and extensive knowledge of these markets to effectively expand its reach.
“Our partnership with PolyMedics Innovations represents the first step of our strategic global expansion,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “Their proven track record and expertise in the global distribution of innovative wound treatments make them an ideal partner. We look forward to a successful collaboration that will enable us to reach more patients worldwide.”
Related: DnaNudge and NantNudge partner to introduce new handheld genomic device
Christian Planck, Chief Executive Officer of PolyMedics Innovations added, “we are excited to partner with AVITA Medical. Our specialized sales team’s deep focus on burns and trauma seamlessly aligns with the targeted procedures for RECELL, and we expect to deliver strong results while elevating the standard of care for patients in Germany, Austria, and Switzerland.”
About AVITA Medical, Inc.
AVITA Medical® is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL® System technology platform, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects and for repigmentation of stable depigmented vitiligo lesions, harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications.
In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
About PolyMedics Innovations GmbH
PolyMedics Innovations (PMI) is a R&D-driven specialist in innovative biomaterials for the effective treatment of wounds. PMI is an owner-managed German Mittelstand Company headquartered in Denkendorf, Germany with a subsidiary in Atlanta, USA. Distribution covers over 40 markets globally. PMI’s state-of-the-art manufacturing plant is located in Germany. PMI is a market leader in burn care in the DACH countries (Germany, Austria, and Switzerland) with a strong presence in the US, LATAM and Asia. The company is renowned for its commitment to delivering innovative medical solutions and services, catering to the diverse needs of healthcare providers and patients. PMI’s portfolio offered to its customers in the DACH region encompasses a range of cutting-edge products, including SUPRATHEL®, NovoSorb® BTM, SUPRA SDRM® and Nexobrid®. With a strong focus on customer access, sales, marketing, and a dedicated medical team, PMI is poised to facilitate rapid and professional expansion in the medical industry.
